All six active ingredients-related companies that re-evaluated their benefit adequacy with the HIRA this year will meet at the negotiating table with the NHIS.

In particular, the components for which the benefit maintenance has been decided will also be negotiated with the NHIS. Streptokinase and Streptodornase will negotiate the recovery according to the results of clinical re-evaluation, and 37 companies are subject to negotiation. Some predict that it will not be easy to meet the 30-day deadline for negotiations.

According to the NHIS on the 18th, a negotiation order for drugs subject to this year's drug benefit adequacy evaluation will be issued from the Ministry of Health and Welfare